Louisiana Files Lawsuit Accusing Fresenius of Withholding GranuFlo Heart Attack Risks
A GranuFlo lawsuit has been filed against Fresenius Medical Care and nearly 100 dialysis clinics in Louisiana that distributed a pair of medications allegedly associated with life-threatening cardiovascular injuries, The Advocate.com reports.
The claim was recently filed in 19th Judicial District Court, the June 30th article indicates, by officials in Louisiana who accuse Fresenius of concealing vital information about GranuFlo and NaturaLyte’s link to serious heart attack risks. According to the state Attorney General’s Office, the dialysis drug and service provider knew as early as 2004 that the medications could elevate bicarbonate levels in the blood stream, leading to a condition known as metabolic alkalosis. Fresenius was also aware that dialysis machines administering GranuFlo and NaturaLyte required special instructions to reduce the risk for heart attacks, sudden cardiac death and other side effects.
1,500 Clinics Unaware of GranuFlo Risks Prior to FDA Alert, Louisiana Lawsuit Alleges
Dialysis patients in Louisiana, along with some 1,500 non-Fresenius facilities using the drugs were unaware of their dangers until March 2012, when the company issued an Urgent Product Notification about GranuFlo and NaturaLyte’s association with serious heart problems. Two months later, the U.S. Food and Drug Administration (FDA) certified the recall as Class I, it’s most serious category.
According to the Advocate, a Fresenius-led study found in 2010 that 941 dialysis patients at 667clinics operating within its network suffered a cardiac arrest during dialysis.
The Louisiana Attorney General’s Office is accusing the company of violating Louisiana’s Unfair Trade Practices and Consumer Protection Law in efforts to defraud physicians and dialysis clinics, as well as the state and its residents. For each violation, the state is entitled to receive $5,000 per violation in civil penalties, and has asked that Fresenius be forced to pay back profits earned from its sales of GranuFlo.
The recently-filed claim from Louisiana’s Attorney General’s Office follows almost 2,000 product liability lawsuits filed by dialysis patients and their families who similarly accuse Fresenius of concealing vital information about its side effects. In a federal litigation established for GranuFlo and NaturaLyte lawsuits, court documents from June 16th indicate that 1,863 claims are now pending in the U.S. District Court, District of Massachusetts, for example.
Pursue a GranuFlo Lawsuit
Contact our Firm today to learn more about GranuFlo lawsuits, and to learn whether you are eligible to file a claim over the dialysis medications. Call us now to learn more about this mounting dialysis litigation at (877) 779-1414.